KBI Biopharma SA and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony at their new state-of-the-art facility in Geneva, Switzerland. Designed to support increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will provide an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond. By co-locating in one facility, KBI and Selexis aim to deliver streamlined and cost-effective services to help clients advance their investigational therapies.
 
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
 
The ~94,000 square-foot facility will house new labs to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance.